{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:08:16Z","timestamp":1782907696114,"version":"3.54.5"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01DK078121"],"award-info":[{"award-number":["1R01DK078121"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01HD36289"],"award-info":[{"award-number":["P01HD36289"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Steroids"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.steroids.2014.12.021","type":"journal-article","created":{"date-parts":[[2015,1,2]],"date-time":"2015-01-02T20:37:27Z","timestamp":1420231047000},"page":"80-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"special_numbering":"C","title":["CYP17A1 inhibitors in castration-resistant prostate cancer"],"prefix":"10.1016","volume":"95","author":[{"given":"Lissette","family":"Gomez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R.","family":"Kovac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores J.","family":"Lamb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.steroids.2014.12.021_b0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0022-5347(05)64820-3","article-title":"Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941","volume":"168","author":"Huggins","year":"2002","journal-title":"J. Urol."},{"key":"10.1016\/j.steroids.2014.12.021_b0010","first-page":"10","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.steroids.2014.12.021_b0015","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/j.juro.2007.03.003","article-title":"Guideline for the management of clinically localized prostate cancer: 2007 update","volume":"177","author":"Thompson","year":"2007","journal-title":"J. Urol."},{"key":"10.1016\/j.steroids.2014.12.021_b0020","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1200\/JCO.2006.10.1949","article-title":"Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline","volume":"25","author":"Loblaw","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.steroids.2014.12.021_b0025","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1056\/NEJM199810083391504","article-title":"Bilateral orchiectomy with or without flutamide for metastatic prostate cancer","volume":"339","author":"Eisenberger","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.steroids.2014.12.021_b0030","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1056\/NEJM198908173210702","article-title":"A controlled trial of leuprolide with and without flutamide in prostatic carcinoma","volume":"321","author":"Crawford","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.steroids.2014.12.021_b0035","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00210-005-0014-5","article-title":"Topiramate augments the antipsychotic-like effect and cortical dopamine output of raclopride","volume":"372","author":"Eltayb","year":"2005","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.steroids.2014.12.021_b0040","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1200\/JCO.1985.3.6.827","article-title":"A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma","volume":"3","author":"Eisenberger","year":"1985","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.steroids.2014.12.021_b0045","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1440-169X.2005.00826.x","article-title":"Identification of asymmetrically localized transcripts along the animal\u2013vegetal axis of the Xenopus egg","volume":"47","author":"Kataoka","year":"2005","journal-title":"Dev. Growth Differ."},{"key":"10.1016\/j.steroids.2014.12.021_b0050","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.steroids.2014.12.021_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-med-121211-091605","article-title":"Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer","volume":"64","author":"Ferraldeschi","year":"2013","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.steroids.2014.12.021_b0060","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1042\/CS20080391","article-title":"Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy","volume":"117","author":"Ramsay","year":"2009","journal-title":"Clin. Sci."},{"key":"10.1016\/j.steroids.2014.12.021_b0065","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1210\/en.2007-0446","article-title":"A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions","volume":"148","author":"Jagla","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.steroids.2014.12.021_b0070","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ccr.2009.11.006","article-title":"Steroid hormone receptors in prostate cancer: a hard habit to break?","volume":"16","author":"Attard","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.steroids.2014.12.021_b0075","first-page":"4511","article-title":"Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes","volume":"57","author":"Lu","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.steroids.2014.12.021_b0080","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/(SICI)1097-0045(20000201)42:2<150::AID-PROS10>3.0.CO;2-H","article-title":"Dysregulated expression of growth factors and their receptors in the development of prostate cancer","volume":"42","author":"Djakiew","year":"2000","journal-title":"Prostate"},{"key":"10.1016\/j.steroids.2014.12.021_b0085","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1210\/mend.13.3.0254","article-title":"Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter","volume":"13","author":"Lu","year":"1999","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.steroids.2014.12.021_b0090","first-page":"5611","article-title":"Androgen blocks apoptosis of hormone-dependent prostate cancer cells","volume":"61","author":"Kimura","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.steroids.2014.12.021_b0095","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.1117679","article-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","volume":"310","author":"Tomlins","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.steroids.2014.12.021_b0100","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature09744","article-title":"The genomic complexity of primary human prostate cancer","volume":"470","author":"Berger","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.steroids.2014.12.021_b0105","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.cell.2009.11.030","article-title":"Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer","volume":"139","author":"Lin","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.steroids.2014.12.021_b0110","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1126\/science.1178124","article-title":"Induced chromosomal proximity and gene fusions in prostate cancer","volume":"326","author":"Mani","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.steroids.2014.12.021_b0115","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0015-0282(16)43461-8","article-title":"Pituitary gonadotropin inhibition by a highly active analog of luteinizing hormone-releasing hormone","volume":"30","author":"Sandow","year":"1978","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.steroids.2014.12.021_b0120","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0015-0282(16)41963-1","article-title":"Delay of puberty and inhibition of reproductive processes in the rat by a gonadotropin-releasing hormone agonist analog","volume":"27","author":"Johnson","year":"1976","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.steroids.2014.12.021_b0125","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","article-title":"Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth","volume":"68","author":"Montgomery","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.steroids.2014.12.021_b0130","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1158\/0008-5472.CAN-05-4000","article-title":"Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer","volume":"66","author":"Stanbrough","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.steroids.2014.12.021_b0135","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1158\/0008-5472.CAN-07-5997","article-title":"Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer","volume":"68","author":"Locke","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.steroids.2014.12.021_b0140","first-page":"803","article-title":"Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays","volume":"59","author":"Bubendorf","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.steroids.2014.12.021_b0145","first-page":"3550","article-title":"Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer","volume":"61","author":"Linja","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.steroids.2014.12.021_b0150","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1210\/mend.15.1.0581","article-title":"Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function","volume":"15","author":"Buchanan","year":"2001","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.steroids.2014.12.021_b0155","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1158\/0008-5472.CAN-08-3605","article-title":"Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy","volume":"69","author":"Steinkamp","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.steroids.2014.12.021_b0160","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1056\/NEJM199505253322101","article-title":"Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer","volume":"332","author":"Taplin","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.steroids.2014.12.021_b0165","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/humu.20848","article-title":"Pleiotropic functional properties of androgen receptor mutants in prostate cancer","volume":"30","author":"Bergerat","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.steroids.2014.12.021_b0170","doi-asserted-by":"crossref","first-page":"16759","DOI":"10.1073\/pnas.1012443107","article-title":"Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor","volume":"107","author":"Watson","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.steroids.2014.12.021_b0175","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/pros.20170","article-title":"Androgen receptor corepressors: an overview","volume":"63","author":"Wang","year":"2005","journal-title":"Prostate"},{"key":"10.1016\/j.steroids.2014.12.021_b0180","first-page":"4315","article-title":"A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy","volume":"61","author":"Gregory","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.steroids.2014.12.021_b0185","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1677\/ERC-08-0084","article-title":"Androgen receptor and growth factor signaling cross-talk in prostate cancer cells","volume":"15","author":"Zhu","year":"2008","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.steroids.2014.12.021_b0190","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/6495","article-title":"A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2\/neu tyrosine kinase","volume":"5","author":"Craft","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.steroids.2014.12.021_b0195","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/1078-0432.CCR-1146-03","article-title":"The androgen axis in recurrent prostate cancer","volume":"10","author":"Mohler","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.steroids.2014.12.021_b0200","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s11912-011-0153-4","article-title":"Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer","volume":"13","author":"Salem","year":"2011","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.steroids.2014.12.021_b0205","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1055\/s-2004-861547","article-title":"Adrenal androgens and intracrinology","volume":"22","author":"Labrie","year":"2004","journal-title":"Semi. Reprod. Med."},{"key":"10.1016\/j.steroids.2014.12.021_b0210","first-page":"944","article-title":"Androgen receptor mutations in prostate cancer","volume":"60","author":"Marcelli","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.steroids.2014.12.021_b0215","first-page":"2643","article-title":"HER-2\/neu (p185neu) protein expression in the natural or treated history of prostate cancer","volume":"7","author":"Osman","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.steroids.2014.12.021_b0220","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1093\/jnci\/92.23.1918","article-title":"Her-2-neu expression and progression toward androgen independence in human prostate cancer","volume":"92","author":"Signoretti","year":"2000","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.steroids.2014.12.021_b0225","doi-asserted-by":"crossref","first-page":"8253","DOI":"10.1200\/JCO.2005.03.4777","article-title":"Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis","volume":"23","author":"Scher","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.steroids.2014.12.021_b0230","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","volume":"26","author":"Berthold","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.steroids.2014.12.021_b0235","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.steroids.2014.12.021_b0240","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.steroids.2014.12.021_b0245","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.steroids.2014.12.021_b0250","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0022-5347(05)64675-7","article-title":"Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer","volume":"168","author":"Harris","year":"2002","journal-title":"J. Urol."},{"key":"10.1016\/j.steroids.2014.12.021_b0255","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0022-5347(01)64924-3","article-title":"Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal","volume":"157","author":"Small","year":"1997","journal-title":"J. Urol."},{"key":"10.1016\/j.steroids.2014.12.021_b0260","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.beem.2008.01.009","article-title":"A role for the androgen-receptor in clinically localized and advanced prostate cancer","volume":"22","author":"Mohler","year":"2008","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.steroids.2014.12.021_b0265","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0002-9440(10)63112-4","article-title":"Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance","volume":"164","author":"Holzbeierlein","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.steroids.2014.12.021_b0270","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/1756287212452196","article-title":"Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born","volume":"4","author":"Schweizer","year":"2012","journal-title":"Ther. Adv. Urol."},{"key":"10.1016\/j.steroids.2014.12.021_b0275","first-page":"875","article-title":"Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer","volume":"7","author":"Semenas","year":"2013","journal-title":"Drug Des. Develop. Ther."},{"key":"10.1016\/j.steroids.2014.12.021_b0280","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/0022-4731(87)90511-5","article-title":"Inhibition of testicular 17 alpha-hydroxylase and 17,20-lyase but not 3 beta-hydroxysteroid dehydrogenase-isomerase or 17 beta-hydroxysteroid oxidoreductase by ketoconazole and other imidazole drugs","volume":"28","author":"Ayub","year":"1987","journal-title":"J. Steroid Biochem."},{"key":"10.1016\/j.steroids.2014.12.021_b0285","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1507\/endocrj1954.34.105","article-title":"Ketoconazole as a possible universal inhibitor of cytochrome P-450 dependent enzymes: its mode of inhibition","volume":"34","author":"Higashi","year":"1987","journal-title":"Endocr. J."},{"key":"10.1016\/j.steroids.2014.12.021_b0290","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1055\/s-2004-861545","article-title":"Overview of dehydroepiandrosterone biosynthesis","volume":"22","author":"Auchus","year":"2004","journal-title":"Semi. Reprod. Med."},{"key":"10.1016\/j.steroids.2014.12.021_b0295","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1158\/0008-5472.CAN-08-4531","article-title":"Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven","volume":"69","author":"Attard","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.steroids.2014.12.021_b0300","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/clpt.2011.275","article-title":"Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor","volume":"91","author":"Bryce","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.steroids.2014.12.021_b0305","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/0960-0760(92)90325-D","article-title":"Molecular basis of 17alpha-hydroxylase\/17,20-lyase deficiency","volume":"43","author":"Yanase","year":"1992","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.steroids.2014.12.021_b0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/000992280104000101","article-title":"Congenital adrenal hyperplasia: from genetics and biochemistry to clinical practice, Part 1","volume":"40","author":"Collett-Solberg","year":"2001","journal-title":"Clin. Pediatr."},{"key":"10.1016\/j.steroids.2014.12.021_b0315","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/sj.bjc.6601879","article-title":"Hormonal impact of the 17alpha-hydroxylase\/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer","volume":"90","author":"O\u2019Donnell","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.steroids.2014.12.021_b0320","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"Attard","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.steroids.2014.12.021_b0325","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1158\/1078-0432.CCR-11-0815","article-title":"Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response","volume":"17","author":"Ryan","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.steroids.2014.12.021_b0330","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2009.24.6819","article-title":"Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate","volume":"28","author":"Reid","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.steroids.2014.12.021_b0335","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1200\/JCO.2009.25.9259","article-title":"Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer","volume":"28","author":"Danila","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.steroids.2014.12.021_b0340","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.steroids.2014.12.021_b0345","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.steroids.2014.12.021_b0350","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.1158\/0008-5472.CAN-11-0532","article-title":"Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors","volume":"71","author":"Cai","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.steroids.2014.12.021_b0355","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.1158\/1078-0432.CCR-11-0728","article-title":"Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants","volume":"17","author":"Mostaghel","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.steroids.2014.12.021_b0360","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1200\/JCO.2010.33.7675","article-title":"Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone","volume":"30","author":"Efstathiou","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.steroids.2014.12.021_b0365","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1158\/0008-5472.CAN-11-3980","article-title":"Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100","volume":"72","author":"Richards","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.steroids.2014.12.021_b0370","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1158\/1078-0432.CCR-12-0908","article-title":"Abiraterone inhibits 3beta-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer","volume":"18","author":"Li","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.steroids.2014.12.021_b0375","doi-asserted-by":"crossref","first-page":"6572","DOI":"10.1158\/1078-0432.CCR-04-0477","article-title":"High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence","volume":"10","author":"Ayala","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.steroids.2014.12.021_b0380","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","article-title":"Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer","volume":"19","author":"Carver","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.steroids.2014.12.021_b0385","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/pros.20541","article-title":"The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells","volume":"67","author":"Saporita","year":"2007","journal-title":"Prostate"},{"key":"10.1016\/j.steroids.2014.12.021_b0390","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1158\/0008-5472.CAN-03-3998","article-title":"Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer","volume":"64","author":"Rocchi","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.steroids.2014.12.021_b0395","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1379\/1466-1268(2002)007<0055:EOGOAR>2.0.CO;2","article-title":"Effect of geldanamycin on androgen receptor function and stability","volume":"7","author":"Vanaja","year":"2002","journal-title":"Cell Stress Chaperones"},{"key":"10.1016\/j.steroids.2014.12.021_b0400","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00001813-200404000-00011","article-title":"17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models","volume":"15","author":"Burger","year":"2004","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.steroids.2014.12.021_b0405","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/jnci\/91.22.1940","article-title":"DT-diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90","volume":"91","author":"Kelland","year":"1999","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.steroids.2014.12.021_b0410","first-page":"986","article-title":"17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2\/neu and inhibits the growth of prostate cancer xenografts","volume":"8","author":"Solit","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.steroids.2014.12.021_b0415","doi-asserted-by":"crossref","first-page":"8386","DOI":"10.1158\/0008-5472.CAN-09-1504","article-title":"Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer","volume":"69","author":"Gan","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.steroids.2014.12.021_b0420","doi-asserted-by":"crossref","first-page":"6383","DOI":"10.1016\/j.bmc.2011.08.066","article-title":"Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer","volume":"19","author":"Kaku","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.steroids.2014.12.021_b0425","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jsbmb.2012.01.001","article-title":"Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys","volume":"129","author":"Yamaoka","year":"2012","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.steroids.2014.12.021_b0430","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11912-013-0300-1","article-title":"Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor","volume":"15","author":"Zhu","year":"2013","journal-title":"Current Oncol. Rep."},{"key":"10.1016\/j.steroids.2014.12.021_b0435","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1158\/1535-7163.MCT-08-0336","article-title":"17alpha-Hydroxylase\/17,20 lyase inhibitor VN\/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response","volume":"7","author":"Bruno","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.steroids.2014.12.021_b0440","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1158\/1535-7163.MCT-08-0230","article-title":"Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase\/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer","volume":"7","author":"Vasaitis","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.steroids.2014.12.021_b0445","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1021\/jm040202w","article-title":"Novel C-17-heteroaryl steroidal CYP17 inhibitors\/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model","volume":"48","author":"Handratta","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.steroids.2014.12.021_b0450","doi-asserted-by":"crossref","first-page":"13958","DOI":"10.3390\/ijms140713958","article-title":"Recent progress in pharmaceutical therapies for castration-resistant prostate cancer","volume":"14","author":"Yin","year":"2013","journal-title":"Int. J. Mol. Sci."}],"container-title":["Steroids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X14003146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X14003146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:03:04Z","timestamp":1778709784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039128X14003146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":90,"alternative-id":["S0039128X14003146"],"URL":"https:\/\/doi.org\/10.1016\/j.steroids.2014.12.021","relation":{},"ISSN":["0039-128X"],"issn-type":[{"value":"0039-128X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CYP17A1 inhibitors in castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Steroids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.steroids.2014.12.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}